Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Loss of retinal tension and permanent decrease in retinal function: a new porcine model of rhegmatogenous retinal detachment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and histopathological signatures of optic disc drusen based on microscopy of 1713 enucleated eyes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Primary congenital glaucoma in Denmark, 1977-2016

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reply: Is automated screening for DR indeed not yet ready as stated by Grauslund et al?

    Research output: Contribution to journalLetterResearchpeer-review

  2. Spectral-domain optical coherence tomography of retinal vessels in Waldenström's macroglobulinemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Melanopsin-mediated pupillary light reflex and sleep quality in patients with normal tension glaucoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. An Expanded Test Panel for Assessment of Fringe Benefits From Cataract Surgery

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

PURPOSE: To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines.

METHODS: Retrospective cohort study of 566 eyes in 566 patients with centre-involved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region. Data were retrieved from a database and patient records between January 2011 and March 2016 and analysed using mixed-model statistics.

RESULTS: At the conclusion of follow-up, 24.6% were in active ranibizumab follow-up, 25.4% had switched to other intravitreal pharmacotherapy, 31.6% had been discontinued because of disease stability, 13.8% had been lost to follow-up, 1.4% had been discontinued because of low visual acuity (VA), and 3.2% had died. At baseline, mean best-corrected visual acuity (BCVA) and mean central subfield thickness (CST) were 64.9 (±15.0) letters and 400.2 (±120.3) μm. Mean change in BCVA and mean change in CST from baseline to 3, 12, 24, 36 and 48 months of follow-up were +3.9, +3.5, +2.7, +1.8, +2.3 letters and -97.4, -102.6, -106.9, -105.9, -131.6 μm, respectively. Mean number of injections was 6.1 in year 1 and 1.8 in year 4. In 93 patients, drug switching to aflibercept showed no difference between the two drugs on BCVA or CST. In 79 patients, CST decreased <10% compared to baseline during the first year.

CONCLUSION: In a single-centre clinical setting, 566 patients treated for DME with ranibizumab according to the Danish national guidelines were followed for up to 4 years. Best-corrected visual acuity (BCVA) outcomes are in the low end of clinical studies, but studied on a wider population and achieved with fewer injections.

Original languageEnglish
JournalActa Ophthalmologica
Volume96
Issue number3
Pages (from-to)267-278
Number of pages11
ISSN1755-375X
DOIs
Publication statusPublished - May 2018

    Research areas

  • Journal Article

ID: 52168424